Bio-Techne Stock

Bio-Techne Net Income

The Net Income of Bio-Techne (TECH) as of Aug 15, 2026 is 181.86 M USD. In the previous year, Net Income was 73.40 M USD — a change of 147.77% (higher).

Net Income

181.86 MUSD

YoY

147.77%

Last updated:

In 2026, Bio-Techne's profit amounted to 181.86 M USD, a 147.77% increase from the 73.40 M USD profit recorded in the previous year.

The Bio-Techne Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

NET INCOME (M USD)
Date
NET INCOME (M USD)
Jan 1, 2023
285.26 base
Jan 1, 2024
168.11 base
Jan 1, 2025
73.40 base
Jan 1, 2026
181.86 base
Jan 1, 2027 (e)
326.38 base
Jan 1, 2028 (e)
370.22 base
Jan 1, 2029 (e)
427.24 base
Jan 1, 2030 (e)
424.85 base
YEARNET INCOME (M USD)
2030 est 424.85
2029 est 427.24
2028 est 370.22
2027 est 326.38
2026 181.86
2025 73.40
2024 168.11
2023 285.26
2022 272.05
2021 140.41
2020 229.30
2019 96.07
2018 125.35
2017 77.29
2016 104.48
2015 107.74
2014 110.95
2013 112.56
2012 112.33
2011 112.30
2010 109.78
2009 105.24
2008 103.56
2007 85.11
Access this data via the Eulerpool API

Bio-Techne Revenue

Bio-Techne Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.14 B USD
306.75 M USD
285.26 M USD
Jan 1, 2024
1.16 B USD
206.69 M USD
168.11 M USD
Jan 1, 2025
1.22 B USD
106.97 M USD
73.40 M USD
Jan 1, 2026
1.22 B USD
251.89 M USD
181.86 M USD
Jan 1, 2027 (e)
1.26 B USD
258.96 M USD
326.38 M USD
Jan 1, 2028 (e)
1.38 B USD
283.85 M USD
370.22 M USD
Jan 1, 2029 (e)
1.51 B USD
310.66 M USD
427.24 M USD
Jan 1, 2030 (e)
1.56 B USD
320.11 M USD
424.85 M USD

Bio-Techne Margins

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
67.72 %
26.99 %
25.10 %
Jan 1, 2024
66.41 %
17.83 %
14.50 %
Jan 1, 2025
64.80 %
8.77 %
6.02 %
Jan 1, 2026
65.77 %
20.73 %
14.97 %
Jan 1, 2027 (e)
65.77 %
20.49 %
25.82 %
Jan 1, 2028 (e)
65.77 %
20.53 %
26.77 %
Jan 1, 2029 (e)
65.77 %
20.53 %
28.23 %
Jan 1, 2030 (e)
65.77 %
20.53 %
27.24 %

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Bio-Techne's Profit Margins

The profit margins of Bio-Techne represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Bio-Techne's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Bio-Techne's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Bio-Techne's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Bio-Techne’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Bio-Techne stock

Net Income of Bio-Techne is 181.86 M USD in 2026.

Net Income of Bio-Techne changed from 73.40 M USD to 181.86 M USD, representing a 147.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Bio-Techne historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

Income Statement — Bio-Techne

All Key Metrics — Bio-Techne